Seres Therapeutics Inc (MCRB) — Cash Flow-to-Debt Ratio
Seres Therapeutics Inc (MCRB) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of $2.21 Million could theoretically repay 0% of its total liabilities ($99.78 Million) in one year. See Seres Therapeutics Inc (MCRB) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seres Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Seres Therapeutics Inc across 13 annual periods. Also explore MCRB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Seres Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Seres Therapeutics Inc. For market capitalisation and broader financial context, see Seres Therapeutics Inc (MCRB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.18x | $-148.61 Million | $126.03 Million | ▼ -305.4% |
| 2023 | -0.29x | $-117.35 Million | $403.46 Million | ▲ +57.0% |
| 2022 | -0.68x | $-228.82 Million | $338.00 Million | ▼ -2360.8% |
| 2021 | 0.03x | $6.69 Million | $223.35 Million | ▲ +105.4% |
| 2020 | -0.56x | $-93.61 Million | $168.19 Million | ▼ -31.5% |
| 2019 | -0.42x | $-76.52 Million | $180.76 Million | ▼ -13.5% |
| 2018 | -0.37x | $-62.85 Million | $168.52 Million | ▲ +36.4% |
| 2017 | -0.59x | $-75.52 Million | $128.82 Million | ▼ -286.9% |
| 2016 | 0.31x | $43.92 Million | $140.01 Million | ▲ +108.8% |
| 2015 | -3.55x | $-40.84 Million | $11.51 Million | ▼ -4837.3% |
| 2014 | -0.07x | $-10.36 Million | $144.07 Million | ▲ +98.0% |
| 2013 | -3.56x | $-5.32 Million | $1.49 Million | ▲ +78.3% |
| 2012 | -16.43x | $-2.92 Million | $178.00K | — |